Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Solid Tumors × olaparib × Clear all

Phase

Status

Sponsor Class

INDUSTRY 3 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Ovarian Neoplasms 41 Breast Neoplasms 34 Prostatic Neoplasms 16 Triple Negative Breast Neoplasms 15 Neoplasms 11 Fallopian Tube Neoplasms 10 Endometrial Neoplasms 10 Pancreatic Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 7 Small Cell Lung Carcinoma 7 Recurrence 7 Neoplasm Metastasis 5 Carcinoma, Ovarian Epithelial 5 Sarcoma 4 Lung Neoplasms 4 Glioma 4 Glioblastoma 4 Carcinoma, Squamous Cell 4 Advanced Breast Cancer 4 Uterine Cervical Neoplasms 3 Stomach Neoplasms 3 Solid Tumor 3 Head and Neck Neoplasms 3 Fanconi Anemia, Complementation Group D1 3 Carcinoma, Non-Small-Cell Lung 3 Uveal Melanoma 2 Uterine Neoplasms 2 Urinary Bladder Neoplasms 2 Sarcoma, Ewing 2 Neuroendocrine Tumors 2

Interventions

Sunitinib 4 Cyclophosphamide 4 Capecitabine 4 Bevacizumab 4 pazopanib 3 Topotecan 3 Paclitaxel 3 Docetaxel 3 Carboplatin 3 temsirolimus 2 liposomal doxorubicin 2 fludarabine 2 Sorafenib 2 Panobinostat 2 NVP-BKM120 2 Lapatinib 2 Irinotecan 2 Immune Checkpoint Inhibitors 2 Gemcitabine 2 Everolimus 2 Erlotinib Hydrochloride 2 Doxorubicin 2 Bortezomib 2 vadimezan 1 spartalizumab 1 somatostatin receptor 2 1 selinexor 1 selicrelumab 1 perifosine 1 pegylated granulocyte colony-stimulating factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07018622 2026-03-11

DAPA-ARMOR

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡